EXTENDED REPORTS

Demonstration of mast cell chemotactic activity in synovial fluid from rheumatoid patients

N Olsson, A-K Ulfgren, G Nilsson

Abstract

Objectives—The significance of the mast cell in the pathogenesis of rheumatic diseases has become more evident. Although mast cell hyperplasia is a feature of rheumatoid arthritis, the nature of mast cell chemoattractants involved in the recruitment of mast cells in joint diseases has not been studied in any detail. In this study the presence of mast cell chemotactic activity in synovial fluids was examined.

Methods—Synovial fluids from seven rheumatoid patients were tested in a modified Boyden chamber, where a human mast cell line was used as responder. The presence of stem cell factor (SCF) and transforming growth factor β (TGF β) was measured by enzyme linked immunosorbent assay (ELISA).

Results—Six of the seven synovial fluids tested exhibited mast cell chemotactic activity. Two characterised human mast cell chemotaxins, SCF and TGF β , were highly expressed in the synovium. Soluble SCF could be detected in all fluids analysed. Blocking antibodies against SCF or TGF β almost completely blocked the activity in one fluid, partially blocked the activity in three, and did not affect the activity in two. Treatment of the responder cells with pertussis toxin reduced the migratory response against seven fluids, indicating the presence of chemoattractants mediating their effect through G $_i$ coupled receptors.

Conclusion—These data demonstrate the presence of multiple factors in synovial fluid acting as mast cell chemoattractants, two of which are SCF and TGF β that contribute to the effect. These findings may be of importance for developing new strategies to inhibit mast cell accumulation in rheumatic diseases.

(*Ann Rheum Dis* 2001;60:187–193)

Department of
Genetics and
Pathology, Uppsala
University, Uppsala,
Sweden
N Olsson
G Nilsson

Department of
Medicine, Unit of
Rheumatology,
Karolinska Hospital,
Stockholm, Sweden
A-K Ulfgren

Correspondence to:
Dr G Nilsson, Department
of Genetics and Pathology,
Rudbeck Laboratory,
Uppsala University, S-751 85
Uppsala, Sweden
Gunnar.Nilsson@genpat.uu.se

Accepted 25 July 2000

space upon activation.² Activated mast cells also synthesise prostaglandins and leucotrienes, and release both preformed and newly synthesised cytokines such as tumour necrosis factor α .^{2–3} Thus mast cells can release an array of mediators with the potential to cause inflammation and tissue remodelling. Therefore the mast cell is now considered to have a pivotal role in arthritis.^{4–6}

Several histological studies have reported that mast cells are present in normal human synovia.^{7–9} Furthermore, mast cell hyperplasia has been described in rheumatoid synovial membranes.^{10–12} The mast cells are distributed throughout the synovial tissue as well as being present in the synovial fluid.¹³ The degree of mast cell hyperplasia in synovial tissues seems to be related to the degree of clinical synovitis and lymphocytic infiltration.¹⁴ The localisation of mast cells at the cartilage-pannus junction and in areas of matrix metalloproteinase deposition suggests a role for these cells in matrix remodelling.^{15–16} In addition, levels of mast cell mediators, including histamine, heparin, chymase, and tryptase, are increased in synovial fluids, indicating continuing mast cell activation.^{4–17–18} Administration of corticosteroids results in clinical improvement and can be accompanied by a decrease in mast cell numbers.¹⁴ These findings suggest that mast cells and their mediators may contribute to the initiation and progression of the destructive inflammatory process of rheumatoid arthritis.

The cause of mast cell hyperplasia in rheumatoid arthritis is not known. One possibility is an increased recruitment of mast cells and mast cell progenitors from other tissues into the inflamed joint. The recent reports that stem cell factor (SCF) and transforming growth factor β 1 (TGF β 1) are mast cell chemoattractants have provided support for this hypothesis.^{19–21} The present study aimed at determining whether synovial fluid contains mast cell chemotactic activity.

Materials and methods

PATIENTS

Patients with active rheumatoid arthritis, as defined by the American College of Rheumatology Criteria,²² were recruited from the open care unit at the Department of Rheumatology, Karolinska Hospital, Stockholm. All were newly diagnosed (less than one year from

Mast cells are inflammatory cells with importance for both acute and chronic inflammatory processes.¹ These cells store a number of mediator molecules in their granules, such as histamine, heparin, and proteases, and can release these mediators into the extracellular

Table 1 Description of patients

Patient No	Age	Sex	Diagnosis	Treatment
RD1	24	Female	RA	NSAIDs
RD2	75	Male	RA	NSAIDs
RD3	45	Male	RA	—
RD4	49	Female	RA	NSAIDs
RD5	27	Female	RA	NSAIDs, IL1ra
RD6	68	Male	OA	Prednisolone
RD7	22	Female	Polyarthritis seronegative	—

NSAIDs = non-steroidal anti-inflammatory drugs; OA = osteoarthritis; RA = rheumatoid arthritis; — = no treatment; IL1ra = interleukin 1 receptor antagonist.

appearance) and with active arthritis (joint pain and swollen joints). Table 1 summarises details of the patients. Biopsy specimens from patients with hallux valgus served as controls.²³

SYNOVIAL FLUIDS AND BIOPSY SPECIMENS

Synovial fluids and biopsy specimens were taken from the knee joint. The fluids were obtained in heparinised vials, centrifuged at 1400×g for 10 minutes, and supernatants frozen at -70°C until investigation. Biopsy specimens were obtained by arthroscopy guided techniques and immediately snap frozen in isopentane on dry ice. All tissues were stored at -70°C until sectioned.

PREPARATION OF TISSUE SECTIONS AND IMMUNOSTAINING

For each monoclonal antibody two cryostat sections, 6–8 µm thick, were mounted on gelatin coated glass slides (Cel-Line, Newfield, USA). The slides were fixed in 50% cold acetone for 30 seconds, followed by 100% cold acetone. Endogenous peroxidase activity was blocked by 0.3% hydrogen peroxide in phosphate buffered saline (PBS) for one hour in the dark. After three additional washes in PBS the slides were incubated overnight at room temperature in a humid chamber with 100 µl of specific monoclonal antibody (antitryptase, monoclonal antibody 1222 from Chemicon International, London, UK, and anti-SCF, Genzyme Diagnostics, Cambridge, MA) dissolved in PBS containing 1% bovine serum albumin and 0.02% NaN₃. The presence of TGFβ isoforms was determined as previously described²⁴ using affinity purified rabbit polyclonal antibodies: TGFβ1, No 96, TGFβ2, No 94, and TGFβ3, No 95 (kindly provided by Dr Keiko Funo, Gothenburg University, Sweden). Control staining was performed in parallel with isotype control (Dakopatts, Copenhagen, Denmark). After incubation with primary antibodies, slides were washed three times with PBS and incubated with 1% normal horse serum in PBS for 15 minutes at room temperature. Secondary antibodies (biotin-horse-antimouse IgG1, Vector Laboratory, Burlingame, CA), were added for 30 minutes at room temperature. After three washes with PBS, avidin-biotin-peroxidase (ABC) complexes (Vectastain ABC-HP kit standard, Vector Laboratory) were added for 45 minutes at room temperature. The colour reaction was developed for 15 minutes with 2.5 mg/ml AEC (3-amino-9-ethylcarbazole in 0.02 M sodium acetate pH 5.5 with 0.003% H₂O₂), generating a red colour. Counterstaining was performed with Mayer's haematoxylin for 1–5 minutes

and the sections were mounted in glycerin-gelatin (Kaisers glycerin-gelatin, Merck, Darmstadt, Germany).

To test the specificity of the staining of the cytokine producing cells, blocking experiments were also performed for all antibodies used in the experiments. Recombinant cytokines were incubated with primary antibody at 10 times excess of the antibody concentration (20 µg/ml) at 4°C overnight. Subsequent staining was performed as described.

COMPUTER AIDED IMAGE ANALYSIS

Stainings were examined with a Polyvar II microscope (Reichert-Jung, Vienna, Austria). Tissue sections were evaluated by computer aided image analysis as previously described.²⁵ Briefly, the microscope was equipped with a three-chip charged couple device colour camera (DXC-750P, Sony Corporation, Tokyo, Japan) that digitised the microscope images to be processed in a Quantimet 600S image analyser (Leica Cambridge, Cambridge, UK) linked to a PC computer. The images were simultaneously transferred by the videocamera to a monitor, where the analytical decisions made by the computer were displayed in discriminating pseudocolours. This enabled the operator to accept or discard the result of analysis of a given field. A special software program (Posarea) was written in the high level language QUIPS and used to detect positively stained areas of the synovial tissue.²⁵ Each microscope field was quantified using selected colour detection threshold values of single pixels in the digital image. The computer was then able to quantify the detected pixels to measure the area occupied by a specific staining of cytokines or of cells and express the results as a percentage of the total tissue area that was studied. A reading of an entire tissue section typically involved 50–200 microscope fields using a magnification power of ×250.

MEASUREMENTS OF CYTOKINE LEVELS IN SYNOVIAL FLUID

Measurements of TGFβ and SCF concentrations in synovial fluids were made by an enzyme linked immunoassay (ELISA) kit (sensitivity TGFβ 5 pg/ml and SCF 4 pg/ml) (R&D Systems, Abingdon, UK).

MAST CELL CULTURES

The human mast cell line, HMC-1, was established from a patient with mast cell leukaemia,²⁶ and exhibited a phenotype of immature mast cells.²⁷ HMC-1 cells were cultured in Iscove's modified Dulbecco's medium supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, 100 IU/ml penicillin, 50 µg/ml streptomycin, and 1.2 mM α-thioglycerol. Cells were passaged every three to four days.

CHEMOTAXIS ASSAY

The migration of HMC-1 cells was assayed in a modified Boyden chamber by the leading front technique as previously described.²⁰ Synovial fluids to be tested were diluted in medium. Thirty microlitres of the attractant

Table 2 Quantification of staining for mast cell tryptase and stem cell factor (SCF) in the synovium

Patient No	Tryptase*	SCF
RD1	9.9	43
RD2	1.6	40
RD3	1.1	NT
RD4	2.0	46
RD5	2.7	34
RD6	9.1	27
RD7	2.8	NT

*The tryptase and SCF data represent the area occupied by the staining for each antibody as a percentage of the total section area. The size of each tissue section ranged from 2 to 9 mm². NT = not tested (lack of material).

was added to each well below the filter, and 50 µl of the cell suspension (1.5×10^6 cells/ml) was added above the filter. After 150 minutes at 37°C and 5% CO₂, the filters were fixed, stained with Mayer's haemalum solution and mounted. The migration of mast cells against medium with 10% FCS served as control and was designated as 100% migration. Cell chemotaxis was assayed as the migration of the two furthest migrating cells visible in focus of one high power field (10×20). The migration distance on each filter was calculated as the mean of the readings of three different areas of the filter. The assay was always performed in triplicate at least.

INHIBITION OF ACTIVITY OF SYNOVIAL FLUID USING ANTI-CYTOKINE ANTIBODIES

Anti-TGFβ (pan-specific TGFβ neutralising antibody, R&D Systems Europe Ltd, Abingdon, UK) and anti-SCF (goat antihuman rSCF, R&D Systems) were added to the substrate suspension just before their addition to the chemotaxis assay. After a dose-response

study of the two antibodies to determine optimal inhibitory concentrations for each agent the following concentrations were used: pan-specific TGFβ neutralising antibody (10 µg/ml), goat antihuman rSCF (10 µg/ml). Species-specific IgG (goat IgG for SCF and rabbit IgG for TGFβ, R&D Systems Europe Ltd) were used as controls at 10 µg/ml.

TREATMENT WITH INHIBITORS

HMC-1 cells were treated with 0.5 µg/ml pertussis toxin (Sigma Chemicals Co, St Louis, MO) or 0.5 µg/ml genistein (Calbiochem-Novabiochem Co, San Diego, CA). Inhibitor treatment was performed by incubating 2.5×10^6 cells/ml for 90 minutes at 37°C and 5% CO₂, with each inhibitor in complete medium. The cells were then washed and resuspended at 1.5×10^6 cells/ml in complete medium before chemotaxis assay.

STATISTICAL ANALYSIS

The data in the text and figures are expressed as means (SEM), unless otherwise stated. Analysis of variance was used for analysis of significant differences. Differences were considered significant at $p < 0.05$. The *t* test for correlation was used for calculation of significance.

Results

STAINING OF MAST CELLS AND STEM CELL FACTOR IN SYNOVIAL MEMBRANE

The number of mast cells is known to increase in the inflamed synovial tissue in arthritis. The most prominent factor for mast cells, important for several aspects of mast cell functions

Figure 1 Immunolocalisation of mast cells and stem cell factor (SCF) in synovial tissue. Tissues were stained for tryptase (A and B) or SCF (C and D). The figures are from the same patient (RD1), but different sections. The stainings are presented at two different magnifications from the same section. Magnification for A and C is $\times 80$, and for B and D $\times 200$.

Figure 2 Migratory response of human cultured mast cells to synovial fluid. The fluid was diluted in medium and tested for mast cell chemotactic activity. Dilutions: undiluted, 5 $\times$, 25 $\times$, 125 $\times$, 250 $\times$, and 500 $\times$. Migration was measured after 150 minutes. The results depicted are from three experiments performed in triplicate. Results are given as means (SEM).

including migration, is stem cell factor. We therefore stained synovial tissue from patients with rheumatic diseases for the presence of mast cell tryptase and stem cell factor. All specimens of rheumatoid synovium indicated the presence of mast cells (table 2), but their distribution and local concentrations were variable. Mast cells were particularly located in the sublining area and in areas around vessels (figs 1A and B). Similarly, all analysed specimens had high expression of SCF (table 2), in both the sublining and the lining areas, and around vessels (figs 1C and D). The cells immunopositive for SCF were identified as synovocytes. Application of isotype control did not give any staining (data not shown).

We also investigated the presence of mast cells and the expression of SCF in the joints from five patients with hallux valgus, who lack signs of chronic inflammation.²³ None of these specimens showed an increase in mast cell numbers or pronounced expression of SCF (negative or slightly positive, data not shown).

Transforming growth factor β has been implicated in the pathogenesis of rheumatic diseases²⁸ and is also a prominent mast cell chemotaxin.²¹ The specimens were therefore analysed for the expression of TGF β isoforms (TGF β 1, TGF β 2, and TGF β 3) and found to be positive (data not shown).

MAST CELL CHEMOTACTIC ACTIVITY IN SYNOVIAL FLUID

To address the issue of migration of mast cells into the inflamed synovial fluid in rheumatic disease, the presence of mast cell chemotactic activity in synovial fluid was analysed using the human mast cell line, HMC-1, in a bioassay. The synovial fluids were tested undiluted or diluted in medium (5–500 times) in a modified Boyden chamber. All except one (RD5) of the synovial fluids showed mast cell chemoattractant activity (fig 2). Five of them had strongest activity at $\times$ 5 dilution and one at $\times$ 125 dilution. Most known chemotaxins induce migration in a bell shaped dose-response curve, where higher concentrations inhibit migration. Thus the results obtained in this study indicate that

Table 3 Comparison of mast cell migration in response to different chemoattractants

Chemoattractant	Migration*
SCF†	143
TGF β 1†	151
Serum amyloid A	157
C3a	256
C5a	145

*Migration of human mast cell, HMC-1, cells in response to optimal concentration of chemoattractant is given as percentage migration compared with control medium.

†SCF = stem cell factor; TGF β 1 = transforming growth factor β 1.

Table 4 Measurements of transforming growth factor β (TGF β) and stem cell factor (SCF) in synovial fluid

Patient No	Concentration TGF β (pg/ml)	Concentration SCF (pg/ml)
RD1	BD*	1 859
RD2	BD	3 102
RD3	BD	11 214
RD4	BD	4 634
RD5	BD	1 125
RD6	NT*	NT*
RD7	BD	2 610

*BD = Below detection level; NT = not tested (lack of material).

the synovial fluids contain high concentrations of mast cell chemotactic activity. The optimal dilution of each fluid was used in all subsequent experiments. As a comparison of the migratory response to synovial fluids the efficacy of some of the identified mast cell chemotaxins is shown in table 3. Thus it is evident that the chemotactic activity in the synovial fluids gives a chemotactic response as strong or stronger than most of the identified mast cell chemotaxins.

SCF AND TGF β IN SYNOVIAL FLUID

We and others have earlier reported that SCF and TGF β can induce mast cell migration in vitro.^{19–21} We therefore suggested that the mast cell chemotactic activity in synovial fluids might, at least in part, be attributed to these factors. The presence of SCF and TGF β in synovial fluid was analysed by ELISA. Table 4 shows that SCF could be detected in all fluids tested. In contrast, TGF β could not be detected in any of the fluids. However, TGF β is effective as a chemotaxin at very low concentrations, with an ED₅₀ of 10 fM.²⁹ Thus TGF β might be present in the synovial fluids at levels below the detection limit for the ELISA and still act as a chemoattractant for mast cells.

BLOCKING OF MAST CELL CHEMOTACTIC ACTIVITY WITH ANTIBODIES AGAINST SCF OR TGF β

To test the involvement of SCF and TGF β in the migration of mast cells towards synovial fluids, we used blocking antibodies against SCF and TGF β . The antibodies were added to synovial fluids before the migration assay. Mast cell chemotactic activity was almost completely blocked in one of the fluids, while four were partially blocked and one not affected when treated with anti-SCF (fig 3A). Similarly, antibodies against TGF β completely blocked the activity in one of the fluids, while three were partially blocked and two were not affected (fig 3B). The specificity of the antibodies and the

Figure 3 Inhibition of activity of synovial fluids in mast cell chemotaxis assay by specific antibodies against (A) SCF (10 µg/ml) and (B) TGFβ (10 µg/ml). Open bars = control, filled bars = with antibody. The results are from three experiments performed in triplicate. Results are given as means (SEM). A significant effect was obtained as indicated: * $p < 0.05$, *** $p < 0.001$.

lack of effect of an irrelevant antibody were also tested (data not shown).

INHIBITION OF MAST CELL CHEMOTAXIS TO SYNOVIAL FLUIDS

To analyse further the nature of the mast cell chemotactic activity in synovial fluids we decided to treat the responder cells with different inhibitors which interfere with intracellular signalling. We chose to use pertussis toxin for inhibition of G_i protein coupled receptors (such as complement receptors) and genistein for tyrosine kinase receptors (for example, stem cell factor receptor). Each synovial fluid was used at a dilution giving optimal migration. Figure 4A shows that pertussis toxin treatment reduced the migratory response of the mast cells to several of the fluids. Of particular interest are fluids RD6 and RD7, which were unaffected by treatment with antibodies, but which did not induce migration of pertussis toxin treated cells. Genistein abolished the migratory response to fluid RD3 (fig 4B), which is the same fluid that showed SCF and TGFβ

dependent migration (fig 3A and B). However, other fluids that also seemed to induce SCF and TGFβ dependent migration could still induce migration of genistein treated cells.

Discussion

Our findings show that (a) synovial fluids collected from patients with rheumatic diseases contain mast cell chemotactic activity, (b) SCF and TGFβ are expressed in the synovium and SCF can be detected in the synovial fluids, and (c) the mast cell chemotactic activity in the synovial fluids is due to multiple chemoattractants, of which SCF and TGFβ are two.

Rheumatoid arthritis is a chronic inflammatory disease characterised by synovial hyperplasia and hypertrophy. Only recently has the mast cell been recognised as an important effector cell of the rheumatoid lesion.⁶ One possible cause for the observed mast cell hyperplasia might be proliferation and maturation of resident immature mast cell precursors already present in the tissue. However, it was recently reported that mast cells in the synovial

Figure 4 Analysis of signal transduction pathways which play a part in mediating mast cell chemoattractant activity in synovial fluids. Mast cells were treated with (A) pertussis toxin, or (B) genistein for 90 minutes before chemotaxis assay. The fluids were used at dilutions giving optimal migration. Open bars = control; filled bars = with inhibitor. The results are from three experiments performed in triplicate. Results are given as means (SEM). A significant effect was obtained as indicated: ** $p < 0.01$, *** $p < 0.001$.

membrane of patients with arthritis do not proliferate.³⁰ It is therefore likely that a direct migration of mast cells within tissues is an important mechanism for the increase in mast cell numbers evident in rheumatic diseases. Although mast cells have been considered to be stationary cells in the tissue, with low tendency to migrate, it is now recognised that they can migrate.³¹ We therefore proposed the hypothesis that cells in the synovium secrete factors that can attract mast cells to the synovium, and that mast cell chemotactic activity should be detectable in the synovial fluid. Indeed, six of seven tested synovial fluids contained mast cell chemotactic activity. As has been reported for lymphocytes, maximum activity was found at a 1:5 dilution of the fluids.³² Thus both lymphocyte and mast cell chemotactic activity can be detected in the fluids.

It was determined that two of the known mast cell chemotaxins, SCF and TGF β 1,^{20 21} were expressed in the synovial membrane, and contributed to mast cell chemotactic activity in the synovial fluids. The cells immunopositive for SCF in the synovial membrane were identified as synoviocytes (macrophages and fibroblasts). It was recently reported by Ceponis *et al* that SCF is expressed in the synovial membrane in arthritis.³⁰ Furthermore, the same group has reported that synovial fibroblasts release SCF in vitro that can induce mast cell migration.³³ We confirm their results, but, in addition, we also show that SCF is secreted in vivo and can be detected in synovial fluid. Furthermore, our study points out the complexity of the mast cell chemotactic activity found in synovial fluid. Stem cell factor is probably one part of the activity, but many other factors, as discussed below, are also likely to play a part.

SCF is not only a mast cell chemotaxin but is also important for other mast cell functions, such as growth and differentiation, survival, adhesion, and activation.³⁴ Thus the presence of SCF in the synovium may have important functions both for the activation and survival of the synovial mast cells and might thereby contribute to the increased number of mast cells in the synovium.

Expression of TGF β has been described in the synovium of patients with rheumatoid arthritis, supposedly to be secreted into the synovial fluid.³⁵ All three isoforms of TGF β are expressed in arthritis.³⁶ All the specimens analysed in this study expressed TGF β 1, TGF β 2, and TGF β 3. Although the isoforms have the same potency to induce migration of mast cells in vitro, TGF β 3 is the most effective.²⁹ Mast cell hyperplasia in arthritis may therefore, in part, be due to differential expression of TGF β isoforms in the synovial membrane.

The composition of synovial fluids is complex and it is therefore not surprising that blocking with antibody to single cytokines does not completely block the activity of the fluid. Cytokines other than those studied here have been reported to attract human mast cells, and still more may remain to be discovered.

One approach for delineating the different types of factors mediating mast cell chemotac-

tic activity is to block different receptor signalling pathways using inhibitors. Pertussis toxin was used to block the family of inhibitory guanine nucleotide-binding proteins (G_i). We, and others, have recently reported that factors mediating their effects through receptors sensitive to pertussis toxin treatment, such as C3a, C5a, serum amyloid A, platelet activating factor, and interleukin 8, are mast cell chemotaxins.³⁷⁻⁴² Some of these are expressed in the synovial membrane and are present in the synovial fluid.^{24 43 44} The response of pertussis toxin treated mast cells was reduced to all except one of the fluids (RD4), indicating the presence of chemotaxins mediating their effects through G_i protein coupled receptors. Similarly, inhibition of tyrosine kinases reduced the response to several of the fluids, even to those that showed a decreased chemotactic activity on pertussis toxin treated cells. These results strongly suggest that several factors are present in the synovial fluid that can act as mast cell chemoattractants. We have previously found a similar complexity of mast cell chemoattractants in other body fluids, including nasal lavage from allergic patients and bronchial lavage fluid from asthmatic patients.^{45 46}

One complicating factor in the understanding of the control of cell migration is how different chemotaxins interact with each other. They may be additive or synergistic, but may also counteract each other. We determined that mast cell migration induced by platelet activating factor is attenuated by C5a and SCF (unpublished results).⁴² This might explain the migratory response to RD4 that is attenuated by anti-SCF, but is active on pertussis toxin as well as genistein treated cells. Furthermore, TGF β 1 has been shown to down regulate the response to SCF in several different systems,^{47 48} including migration (Sundström, Olsson, and Nilsson, manuscript in preparation). Although we have clearly shown that synovial fluids contain strong mast cell chemotactic activity, the cross talk and cross desensitisation among receptors for chemotaxins make it difficult to identify the factors mediating the response in each synovial fluid.

In conclusion, synovial fluids contain mast cell chemotactic activity that can have a role in the mast cell hyperplasia evident in rheumatic diseases. SCF could be detected in the synovial fluid, indicating that SCF may play a part not only in the recruitment of mast cells but also in the perpetuation of chronic inflammation by acting as a mast cell survival and activating factor. There have been reports of a correlation between clinical improvements and a decrease in mast cell numbers,^{14 49} and thus inhibiting mast cell migration might decrease the local mast cell hyperplasia and as a consequence reduce the destructive inflammatory process in arthritic diseases.

We thank Anna-Karin Kratz for excellent technical assistance, Drs Staffan Lindblad and Lollo Gröndal for patient material, Drs Lars Klareskog and Ulf Andersson for valuable discussions and critical reading of the manuscript, Dr BA Harris for linguistic advice, and Dr Keiko Funa for antibodies against TGF β isoforms.

This study was supported by the Swedish Association against Rheumatism, the Swedish Foundation for Health Care Sciences and Allergy Research, Ollie and Elov Ericssons Foundation, and King Gustaf V 80-years foundation.

- 1 Metcalfe DD, Baram D, Mekori YA. Mast cells. *Physiol Rev* 1997;77:1033-79.
- 2 Nilsson G, Costa JJ, Metcalfe DD. Mast cells and basophils. In: Gallin JI, Snyderman R, eds. *Inflammation: basic principles and clinical correlates*. Philadelphia, PA: Lippincott-Raven, 1999:97-117.
- 3 Gordon JR, Burd PR, Galli SJ. Mast cells as a source of multifunctional cytokines. *Immunol Today* 1990;11:458-64.
- 4 Mican JM, Metcalfe DD. Arthritis and mast cell activation. *J Allergy Clin Immunol* 1990;86:677-83.
- 5 Wasserman SI. The mast cell and synovial inflammation. Or, what's a nice cell like you doing in a joint like this. *Arthritis Rheum* 1984;27:841-4.
- 6 Marone G. Mast cells in rheumatic disorders: mastermind or workhorse? *Clin Exp Rheumatol* 1998;16:245-9.
- 7 Janes J, McDonald JR. Mast cells: their distribution in various human tissues. *Arch Pathol Lab Med* 1948;45:622-34.
- 8 Lever JD, Ford EHR. Histological, histochemical and electron microscopic observations on synovial membrane. *Anat Rec* 1958;132:525-43.
- 9 Castor CW. The microscopic structure of normal human synovial tissue. *Arthritis Rheum* 1960;3:140-51.
- 10 Wyenne-Roberts CR, Anderson CH, Turano AM, Baron M. Light- and electron-microscopic findings of juvenile rheumatoid arthritis synovium: comparison with normal human synovium. *Semin Arthritis Rheum* 1978;7:287-302.
- 11 Godfrey HP, Ilardi C, Engber W, Graziano FM. Quantification of human synovial mast cells in rheumatoid arthritis and other rheumatic diseases. *Arthritis Rheum* 1984;27:852-6.
- 12 Crisp AJ, Chapman CM, Kirkham SE, Schiller AL, Krane SM. Articular mastocytosis in rheumatoid arthritis. *Arthritis Rheum* 1984;27:845-51.
- 13 Malone DH, Irani AM, Schwartz LB, Barrett KE, Metcalfe DD. Mast cell numbers and histamine levels in synovial fluids from patients with diverse arthritis. *Arthritis Rheum* 1986;29:956-63.
- 14 Malone DG, Wilder RL, Saavedra-Delgado AM, Metcalfe DD. Mast cell numbers in rheumatoid synovial tissues. Correlations with quantitative measures of lymphocytic infiltration and modulation by antiinflammatory therapy. *Arthritis Rheum* 1987;30:130-7.
- 15 Tetlow LC, Woolley DE. Distribution, activation and tryptase/chymase phenotype of mast cells in the rheumatoid lesion. *Ann Rheum Dis* 1995;54:549-55.
- 16 Tetlow LC, Woolley DE. Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies. *Ann Rheum Dis* 1995;54:896-903.
- 17 Ferwin DB, Cleland LG, Jonsson JR, Robertson PW. Histamine levels in human synovial fluid. *J Rheumatol* 1986;13:13-14.
- 18 Buckley MG, Walters C, Wong WM, Cawley MID, Ren S, Schwartz LB, et al. Mast cell activation in arthritis: detection of alpha- and beta-tryptase, histamine and eosinophil cationic protein in synovial fluid. *Clin Sci* 1997;93:363-70.
- 19 Meininger CJ, Yano H, Rottapel R, Bernstein A, Zsebo KM, Zetter BR. The c-kit receptor ligand functions as a mast cell chemoattractant. *Blood* 1992;79:958-63.
- 20 Nilsson G, Butterfield JH, Nilsson K, Siegbahn A. Stem cell factor is a chemotactic factor for human mast cells. *J Immunol* 1994;153:3717-23.
- 21 Gruber BL, Marchese MJ, Kew RR. Transforming growth factor- β 1 mediates mast cell chemotaxis. *J Immunol* 1994;152:5860-7.
- 22 Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988;31:315-24.
- 23 Ulfgren A-K, Gröndal L, Lindblad S, Khademi M, Johnell O, Klareskog L, et al. Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment. *Ann Rheum Dis* 2000;59:439-47.
- 24 Ulfgren A-K, Lindblad S, Klareskog L, Andersson J, Andersson U. Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. *Ann Rheum Dis* 1995;54:654-61.
- 25 Cunnane G, Björk L, Ulfgren A-K, Lindblad S, FitzGerald O, Breshnahan B, et al. Quantitative analysis of synovial membrane inflammation: a comparison between automated and conventional microscopic measurements. *Ann Rheum Dis* 1999;58:493-9.
- 26 Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. *Leuk Res* 1988;12:345-55.
- 27 Nilsson G, Blom T, Kusche GM, Kjellén L, Butterfield JH, Sundström C, et al. Phenotypic characterization of the human mast cell line HMC-1. *Scand J Immunol* 1994;39:489-98.
- 28 Allen JB, Mantley CL, Hand AR, Ohura K, Ellingsworth L, Wahl SM. Rapid onset synovial inflammation and hyperplasia induced by transforming growth factor β . *J Exp Med* 1990;171:231-47.
- 29 Olsson N, Piek E, ten Dijk P, Nilsson G. Mast cell migration in response to members of the TGF- β family. *J Leukoc Biol* 2000;67:350-6.
- 30 Ceponis A, Konttinen YT, Takagi M, Xu J-W, Sorsa T, Matucci-Cerinic M, et al. Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. *J Rheumatol* 1998;25:2304-14.
- 31 Nilsson G, Metcalfe DD. Contemporary issues in mast cell biology. *Allergy Proc* 1996;17:59-63.
- 32 Al-Mughales J, Blyth TH, Hunter JA, Wilkinson PC. The chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines. *Clin Exp Immunol* 1996;106:230-6.
- 33 Kiener HP, Hofbauer R, Tohidast-Akrad M, Walchshofer S, Redlich K, Bitzan P, et al. Tumor necrosis factor α promotes the expression of stem cell factor in synovial fibroblasts and their capacity to induce mast cell chemotaxis. *Arthritis Rheum* 2000;43:164-74.
- 34 Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. *Adv Immunol* 1994;55:1-96.
- 35 Feldmann M, Brennan FM. Role of cytokines in rheumatoid arthritis. *Annu Rev Immunol* 1996;14:397-440.
- 36 Taketazu F, Kato M, Gobl A, Ichijo H, ten Dijke P, Itoh J, et al. Enhanced expression of transforming growth factor- β s and transforming growth factor- β type II receptor in the synovial tissues of patients with rheumatoid arthritis. *Lab Invest* 1994;70:620-30.
- 37 Nilsson G, Johnell M, Hammer CH, Tiffany HL, Nilsson K, Metcalfe DD, et al. C3a and C5a are chemotaxins for mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway. *J Immunol* 1996;157:1693-8.
- 38 Hartmann K, Henz BM, Krüger-Krasagakes S, Kohl J, Burger R, Gühl S, et al. C3a and C5a stimulate chemotaxis of human mast cells. *Blood* 1997;89:2863-70.
- 39 Lippert U, Artuc M, Grützkau A, Möller A, Kenderessy-Szabo A, Schadendorf D, et al. Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells. *J Immunol* 1998;161:2600-8.
- 40 Nilsson G, Mikovits J, Metcalfe DD, Taub DD. Mast cell migratory response to IL-8 is mediated through interaction with chemokine receptor CXCR2/IL-8RB. *Blood* 1999;93:2791-7.
- 41 Olsson N, Siegbahn A, Nilsson G. Serum amyloid A induces mast cell chemotaxis of human mast cells by activating a pertussis toxin-sensitive signal transduction pathway. *Biochem Biophys Res Commun* 1999;254:143-6.
- 42 Nilsson G, Metcalfe DD, Taub DD. Demonstration that platelet-activating factor is capable of activating mast cells and inducing a chemotactic response. *Immunology* 2000;99:314-19.
- 43 Jose PJ, Moss IK, Maini RN, Williams TJ. Measurement of chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. *Ann Rheum Dis* 1990;49:747-52.
- 44 Troughton PR, Platt R, Bird H, El-Manzalawi E, Bassiouni M, Wright V. Synovial fluid interleukin-8 and neutrophil function in rheumatoid arthritis and seronegative polyarthritis. *Br J Rheumatol* 1996;35:1244-51.
- 45 Nilsson G, Hjertson M, Andersson M, Greiff L, Svensson C, Nilsson K, et al. Demonstration of mast cell chemotactic activity in nasal lavage fluid: characterization of one chemotaxin as c-kit ligand, stem cell factor. *Allergy* 1998;53:874-9.
- 46 Olsson N, Rak S, Nilsson G. Characterization of mast cell chemotactic activity in bronchoalveolar lavage fluid collected from asthmatic patients before and during pollen season. *J Allergy Clin Immunol* 2000;105:455-61.
- 47 de Vos S, Brach MA, Asano Y, Ludwig WD, Bettelheim P, Gruss HJ, et al. Transforming growth factor-beta-1 interferes with the proliferation-inducing activity of stem cell factor in myelogenous leukemia blasts through functional down-regulation of the c-kit proto-oncogene product. *Cancer Res* 1993;53:3638-42.
- 48 Mekori YA, Metcalfe DD. Transforming growth factor-beta prevents stem cell factor-mediated rescue of mast cells from apoptosis after IL-3 deprivation. *J Immunol* 1994;153:2194-203.
- 49 Gotis-Graham I, Smith MD, Parker A, McNeil HP. Synovial mast cell responses during clinical improvement in early rheumatoid arthritis. *Ann Rheum Dis* 1998;57:664-71.